Last year after the ASCO meeting in Chicago I declared that there was one particular presentation of the CHAARTED trial that would be a game changer for the treatment of newly diagnosed men with very significant prostate cancer. The game changer was that men diagnosed with significant disease and who were still ADT naive (not [...]
Before I get into the meat of today’s post about enzalutamide, I want to briefly make some personal comments about my absence from this blog. As I had mentioned I have been diagnosed with a fifth primary cancer, appendiceal cancer. It is a rare cancer, which required my having to remove my appendix, a piece [...]
It was announced today that preliminary results from the Phase II STAND trial demonstrates continued and what is described as a robust immune response with Provenge (sipuleucel-T) that continues two years after completing treatment in men with biochemically-recurrent prostate cancer (BRPC). This finding, along with data from the ongoing Phase IV registry PROCEED trial, are [...]
Many men with advanced prostate cancer who are on hormone therapy (ADT) use one of the newer drugs, degarelix (Firmagon) to achieve a state of castration. Degarelix is considered a superior drug for initiating ADT because it is not accompanied with a PSA flare that is common with the older luteinizing hormone-releasing hormone (LHRH) agonists [...]
It was recently discovered that if hormone therapy (ADT) is added to radiation cancer deaths are lowered by nearly 50 % in men with locally advanced prostate cancer aged 76 to 85 compared to men who only received hormone therapy. Prior studies have shown that 40% of men with aggressive prostate cancers are treated with [...]
A small study from one hospital in Norway has suggested that PSA doubling times after surgery may predict the value of salvage radiation therapy alone as a second line form of therapy. Servoll et al carried out a small retrospective analysis of data derived from 76 men treated by salvage external beam radiation therapy (EBRT) [...]
A Small study suggests that alternating testosterone levels may make hormonal therapy work longer A recent very small study was published that might lend a new light on hormone therapy for advanced prostate cancer, Bipolar ADT. This study suggests that a new treatment strategy might be effective where men alternate between low and high levels [...]
There has been some surprising and unexpected news recently reported by John’s Hopkins Kimmel Cancer Center. Testosterone, which is believed to be a feeder of prostate cancer has been found to also suppress some advanced prostate cancers and also may reverse resistance the to the testosterone-blocking drugs (ADT) used to treat advanced prostate cancer. The [...]
Recently there have been a number of conversations in the prostate media around the topic of treating oligometastatic prostate cancer with a curative goal. Oligometastatic prostate cancer describes the disease state where primary treatment has failed as evidenced by an increasing PSA along with scanning evidence of a limited number of lymph nodes involved in [...]
There has been much conversation surrounding the use of intermittent androgen deprivation (IAD) as opposed to continuous androgen deprivation (CAD) in men with prostate cancer who need hormone therapy (ADT). The question that has been at issue is if either method is superior to the other. There have been studies that have concluded that they [...]
